1
|
Radley A, Beer L, Rushdi D, Close H, McBurney S, Mackenzie A, Gourlay A, Barnett A, Grant A, Greig N, Dow E, Sutherland C. Implementation of point-of-care HbA1C instruments into community pharmacies: Initial development of a pathway for robust community testing. Ann Clin Biochem 2024; 61:273-283. [PMID: 37996254 PMCID: PMC11337724 DOI: 10.1177/00045632231219380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/21/2023] [Indexed: 11/25/2023]
Abstract
BACKGROUND Point-of-care (POC) analysers in community settings can provide opportunistic and regular HbA1c monitoring. Community pharmacies in NHS Scotland are utilised by populations at greatest risk of type two diabetes (T2D). This study describes initial development of an HbA1c pathway using a POC analyser in community pharmacies. METHODS The Abbott Afinion analyser was compared in (i) NHS Tayside's Blood Sciences Service and (ii) community pharmacies from four Scottish Health Boards. A side by side comparison with standard operating procedures for HbA1c quantification using 80 T2D patient venous samples. The machine was implemented into 11 community pharmacies and 144 samples obtained from patients for comparison to their recent laboratory HbA1c. Four focus groups examined themes around the intervention and an exit questionnaire was administered. RESULTS Laboratory assessment verified the efficacy of the POC test machine. The value for level 1 quality control was 44 mmol/mol and the mean during testing 42.7 mmol/mol. The greatest percent coefficient of variation (cv) was within-run for both levels of quality control material, at a value of 1.63% and 1.62%, respectively. The analyser performed robustly within the pharmacy assessment, with a mean difference of 1.68 and a standard deviation of 0.71 (CV 0.423). Patients with T2D reported positive experiences of using a pharmacy. The focus groups identified an appreciation of the convenience of pharmacies and of the longitudinal relationships with pharmacy staff. CONCLUSION POC HbA1c analysers can be successfully established in community pharmacies. The target patient group responded positively to the opportunity to use a pharmacy service.
Collapse
Affiliation(s)
- Andrew Radley
- School of Medicine, University of Dundee, Dundee, UK
| | | | | | | | | | | | - Anna Gourlay
- School of Medicine, University of Dundee, Dundee, UK
| | - Anna Barnett
- NHS Research Scotland, Diabetes Network and School of Medicine, University of Dundee, Dundee, UK
| | | | | | - Ellie Dow
- Blood Sciences, NHS Tayside, Dundee, UK
| | | |
Collapse
|
2
|
La Grotta R, Pellegrini V, Prattichizzo F, Amata O, Panella L, Frizziero A, Visconti M, Averame G, Brasesco PC, Calabrese I, Vaccaro O, Ceriello A. Feasibility of a Type 2 Diabetes Prevention Program at Nationwide Level in General Practice: A Pilot Study in Italy. J Clin Med 2024; 13:1127. [PMID: 38398440 PMCID: PMC10888610 DOI: 10.3390/jcm13041127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Revised: 02/13/2024] [Accepted: 02/15/2024] [Indexed: 02/25/2024] Open
Abstract
BACKGROUND Lifestyle interventions halt the progression of prediabetes to frank type 2 diabetes (T2D). However, the feasibility of a diabetes prevention program promoting tailored interventions on a national scale and conducted by primary care physicians is unclear. METHODS General practitioners located in ten different regions throughout Italy enrolled random subjects without known metabolic diseases to identify individuals with prediabetes and prescribe them an intervention based on physical activity. Using a simple stepwise approach, people referring to their primary care physician for any reason were screened for their diabetes risk with a web-based app of the Findrisc questionnaire. Those at risk for T2D, i.e., with a Findrisc score >9, were invited to come back after overnight fasting to measure fasting glycaemia (FG). Those with 100 ≤ FG < 126 mg/dL were considered as people with prediabetes and compiled the Physical Activity Readiness Questionnaire (PAR-Q) to then receive a personalised prescription of physical activity. RESULTS Overall, 5928 people were enrolled and compiled the questionnaire. Of these, 2895 (48.8%) were at risk for T2D. Among these, FG was measured in 2168 subjects (participation rate 75%). The numbers of individuals with undetected prediabetes and T2D according to FG were 755 and 79 (34.8% and 3.6% of those assessing FG), respectively. Of the 755 subjects in the prediabetes range, 739 compiled the PAR-Q and started a personalised program of physical activity (participation rate 97%). Physicians involved in the study reported a mean of 6 min to perform the screening. CONCLUSIONS Overall, these data suggest the feasibility of a national diabetes prevention program developed by general practitioners using a simple stepwise approach starting from a web app to intercept individuals with prediabetes.
Collapse
Affiliation(s)
- Rosalba La Grotta
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Via Fantoli 16/15, 20138 Milan, Italy
| | - Valeria Pellegrini
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Via Fantoli 16/15, 20138 Milan, Italy
| | - Francesco Prattichizzo
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Via Fantoli 16/15, 20138 Milan, Italy
| | - Oriana Amata
- Department of Rehabilitation, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini-Centro Specialistico Ortopedico Traumatologico (CTO), Piazza Cardinal Ferrari 1, 20122 Milan, Italy
| | - Lorenzo Panella
- Department of Rehabilitation, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini-Centro Specialistico Ortopedico Traumatologico (CTO), Piazza Cardinal Ferrari 1, 20122 Milan, Italy
| | - Antonio Frizziero
- Department of Rehabilitation, Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini-Centro Specialistico Ortopedico Traumatologico (CTO), Piazza Cardinal Ferrari 1, 20122 Milan, Italy
- Department of Biomedical, Surgical and Dental Sciences, Università degli Studi di Milano, 20122 Milan, Italy
| | - Marco Visconti
- Consorzio Sanità (Co.S.), Via Marconi 3, 26015 Soresina, Italy
| | - Gabriella Averame
- Consorzio Sanità (Co.S.), Via Marconi 3, 26015 Soresina, Italy
- Medicoopliguria, Via Peschiera 33, 16121 Genova, Italy
| | - Pier Claudio Brasesco
- Consorzio Sanità (Co.S.), Via Marconi 3, 26015 Soresina, Italy
- Medicoopliguria, Via Peschiera 33, 16121 Genova, Italy
| | - Ilaria Calabrese
- Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy
| | - Olga Vaccaro
- Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Via Sergio Pansini, 5, 80131 Naples, Italy
| | - Antonio Ceriello
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) MultiMedica, Via Fantoli 16/15, 20138 Milan, Italy
| |
Collapse
|
3
|
Amirsadri M, Torkpour E. Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran. Res Pharm Sci 2023; 18:210-218. [PMID: 36873274 PMCID: PMC9976058 DOI: 10.4103/1735-5362.367799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Revised: 11/27/2022] [Accepted: 12/05/2022] [Indexed: 01/21/2023] Open
Abstract
Background and purpose Several studies have shown the effectiveness of screening programs in decreasing the costs and disutility of type-2 diabetes and related complications. As there is a growth in the incidence of type-2 diabetes amongst the Iranian population, the cost-effectiveness of performing type-2 diabetes screening tests in community pharmacies of Iran was evaluated in this study from the payer's perspective. The target population consisted of two hypothetical cohorts of 1000 people 40 years of age without a prior diagnosis of diabetes, for the intervention (screening test) and no-screening groups. Experimental approach A Markov model was developed to evaluate the cost-effectiveness and cost-utility of a type-2 diabetes screening test in community pharmacies in Iran. A 30-year time horizon was considered in the model. Three screening programs with 5-year intervals were considered for the intervention group. The evaluated outcomes were quality-adjusted life-years (QALYs) for cost-utility-analysis and life-years-gained (LYG) for cost-effectiveness-analysis. To examine the robustness of the results, one-way and probabilistic-sensitivity analyses were applied to the model. Findings/Results The screening test represented both more effects and higher costs. The incremental effects in the base-case scenario (no-discounting) were estimated to be 0.017 and 0.0004 (approximately 0) for QALYs and LYG, respectively. The incremental cost was estimated to be 2.87 USD/patient. The estimated incremental-cost-effectiveness ratio was 164.77 USD/QALY. Conclusion and implications This study indicated that screening for type-2 diabetes in community pharmacies of Iran could be considered highly cost-effective, as it meets the WHO criteria of the annual GDP per capita ($2757 in 2020).
Collapse
Affiliation(s)
- Mohammadreza Amirsadri
- Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.,Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
| | - Elahe Torkpour
- Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
| |
Collapse
|
4
|
Rondeaux S, Braeckman T, Beckwé M, Biset N, Maesschalck J, Duquet N, De Wulf I, Devroey D, De Vriese C. Diabetes and Cardiovascular Diseases Risk Assessment in Community Pharmacies: An Implementation Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2022; 19:ijerph19148699. [PMID: 35886551 PMCID: PMC9316424 DOI: 10.3390/ijerph19148699] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 07/14/2022] [Accepted: 07/15/2022] [Indexed: 02/04/2023]
Abstract
The implementation of a new service is often challenging when translating research findings into routine clinical practices. This paper presents the results of the implementation study of a pilot project for a diabetes and cardiovascular diseases risk-assessment service in Belgian community pharmacies. To evaluate the implementation of the service, a mixed method was used that follows the RE-AIM framework. During the testing stage, 37 pharmacies participated, including five that dropped out due to a lack of time or COVID-19-related temporary obligations. Overall, 502 patients participated, of which 376 (74.9%) were eligible for according-to-protocol analysis. Of these, 80 patients (21.3%) were identified as being at high risk for the targeted diseases, and 100 (26.6%) were referred to general practice for further investigation. We presented the limited effectiveness and the key elements influencing optimal implementation. Additional strategies, such as interprofessional workshops, a data-sharing platform, and communication campaigns, should be considered to spread awareness of the new role of pharmacists. Such strategies could also promote collaboration with general practitioners to ensure the follow-up of patients at high risk. Overall, this service was considered easy to perform and feasible in practice but would require financial and external support to ensure its effectiveness, sustainability, and larger-scale implementation.
Collapse
Affiliation(s)
- Sarah Rondeaux
- Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium; (S.R.); (N.B.)
| | - Tessa Braeckman
- Department of Family Medicine and Chronic Care, Faculty of Medicine, Vrije Universiteit Brussels (VUB), 1090 Brussels, Belgium; (T.B.); (M.B.); (D.D.)
| | - Mieke Beckwé
- Department of Family Medicine and Chronic Care, Faculty of Medicine, Vrije Universiteit Brussels (VUB), 1090 Brussels, Belgium; (T.B.); (M.B.); (D.D.)
| | - Natacha Biset
- Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium; (S.R.); (N.B.)
| | - Joris Maesschalck
- Association of Pharmacists Belgium, 1000 Brussels, Belgium; (J.M.); (N.D.); (I.D.W.)
| | - Nathalie Duquet
- Association of Pharmacists Belgium, 1000 Brussels, Belgium; (J.M.); (N.D.); (I.D.W.)
| | - Isabelle De Wulf
- Association of Pharmacists Belgium, 1000 Brussels, Belgium; (J.M.); (N.D.); (I.D.W.)
| | - Dirk Devroey
- Department of Family Medicine and Chronic Care, Faculty of Medicine, Vrije Universiteit Brussels (VUB), 1090 Brussels, Belgium; (T.B.); (M.B.); (D.D.)
| | - Carine De Vriese
- Department of Pharmacotherapy and Pharmaceutics, Faculty of Pharmacy, Université Libre de Bruxelles (ULB), 1050 Brussels, Belgium; (S.R.); (N.B.)
- Correspondence: ; Tel.: +32-26-505-310
| |
Collapse
|
5
|
Manon SM, Phuong JM, Moles RJ, Kelly A, Center JR, Luckie K, White C, Carter SR. The role of community pharmacists in delivering interventions for osteoporosis: A systematic review. J Am Pharm Assoc (2003) 2022; 62:1741-1749.e10. [DOI: 10.1016/j.japh.2022.06.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 06/21/2022] [Accepted: 06/28/2022] [Indexed: 11/30/2022]
|
6
|
Li J, Bao Y, Chen X, Tian L. Decision models in type 2 diabetes mellitus: A systematic review. Acta Diabetol 2021; 58:1451-1469. [PMID: 34081206 PMCID: PMC8505393 DOI: 10.1007/s00592-021-01742-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2021] [Accepted: 05/07/2021] [Indexed: 12/21/2022]
Abstract
AIMS To reduce the burden of type 2 diabetes (T2DM), the disease decision model plays a vital role in supporting decision-making. Currently, there is no comprehensive summary and assessment of the existing decision models for T2DM. The objective of this review is to provide an overview of the characteristics and capabilities of published decision models for T2DM. We also discuss which models are suitable for different study demands. MATERIALS AND METHODS Four databases (PubMed, Web of Science, Embase, and the Cochrane Library) were electronically searched for papers published from inception to August 2020. Search terms were: "Diabetes-Mellitus, Type 2", "cost-utility", "quality-of-life", and "decision model". Reference lists of the included studies were manually searched. Two reviewers independently screened the titles and abstracts following the inclusion and exclusion criteria. If there was insufficient information to include or exclude a study, then a full-text version was sought. The extracted information included basic information, study details, population characteristics, basic modeling methodologies, model structure, and data inputs for the included applications, model outcomes, model validation, and uncertainty. RESULTS Fourteen unique decision models for T2DM were identified. Markov chains and risk equations were utilized by four and three models, respectively. Three models utilized both. Except for the Archimedes model, all other models (n = 13) implemented an annual cycle length. The time horizon of most models was flexible. Fourteen models had differences in the division of health states. Ten models emphasized macrovascular and microvascular complications. Six models included adverse events. Majority of the models (n = 11) were patient-level simulation models. Eleven models simulated annual changes in risk factors (body mass index, glycemia, HbA1c, blood pressure (systolic and/or diastolic), and lipids (total cholesterol and/or high-density lipoprotein)). All models reported the main data sources used to develop health states of complications. Most models (n = 11) could deal with the uncertainty of models, which were described in varying levels of detail in the primary studies. Eleven studies reported that one or more validation checks were performed. CONCLUSIONS The existing decision models for T2DM are heterogeneous in terms of the level of detail in the classification of health states. Thus, more attention should be focused on balancing the desired level of complexity against the required level of transparency in the development of T2DM decision models.
Collapse
Affiliation(s)
- Jiayu Li
- Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, 730000, Gansu Province, China
- Clinical Research Center for Metabolic Diseases, No. 204 Donggang west road, Lanzhou, 730000, Gansu Province, China
- School of Clinical Medicine, Ningxia Medical University, Yinchuan, 750004, Ningxia Province, China
| | - Yun Bao
- Clinical Research Center for Metabolic Diseases, No. 204 Donggang west road, Lanzhou, 730000, Gansu Province, China
| | - Xuedi Chen
- Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, 730000, Gansu Province, China
- Clinical Research Center for Metabolic Diseases, No. 204 Donggang west road, Lanzhou, 730000, Gansu Province, China
| | - Limin Tian
- Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, 730000, Gansu Province, China.
- Clinical Research Center for Metabolic Diseases, No. 204 Donggang west road, Lanzhou, 730000, Gansu Province, China.
| |
Collapse
|
7
|
Jalkanen K, Aarnio E, Lavikainen P, Lindström J, Peltonen M, Laatikainen T, Martikainen J. Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis. BMC Health Serv Res 2021; 21:916. [PMID: 34482831 PMCID: PMC8418722 DOI: 10.1186/s12913-021-06948-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2021] [Accepted: 08/24/2021] [Indexed: 11/25/2022] Open
Abstract
Background Early identification of people at elevated risk of type 2 diabetes (T2D) is an important step in preventing or delaying its onset. Pharmacies can serve as a significant channel to reach these people. This study aimed to assess the potential health economic impact of screening and recruitment services in pharmacies in referring people to preventive interventions. Methods A decision analytic model was constructed to perform a cost-utility analysis of the expected national health economic consequences (in terms of costs and quality-adjusted life years, QALYs) of a hypothetical pharmacy-based service where people screened and recruited through pharmacies would participate in a digital lifestyle program. Cost-effectiveness was considered in terms of net monetary benefit (NMB). In addition, social return on investment (SROI) was calculated as the ratio of the intervention and recruitment costs and the net present value of expected savings. Payback time was the time taken to reach the break-even point in savings. In the base scenario, a 20-year time horizon was applied. Probabilistic and deterministic sensitivity analyses were applied to study robustness of the results. Results In the base scenario, the expected savings from the pharmacy-based screening and recruitment among the reached target cohort were 255.3 m€ (95% CI − 185.2 m€ to 717.2 m€) in pharmacy visiting population meaning 1412€ (95% CI − 1024€ to 3967€) expected savings per person. Additionally, 7032 QALYs (95% CI − 1344 to 16,143) were gained on the population level. The intervention had an NMB of 3358€ (95% CI − 1397€ to 8431€) using a cost-effectiveness threshold of 50,000 €/QALY. The initial costs were 122.2 m€ with an SROI of 2.09€ (95% CI − 1.52€ to 5.88€). The expected payback time was 10 and 8 years for women and men, respectively. Results were most sensitive for changes in effectiveness of the intervention and selected discount rate. Conclusions T2D screening and recruitment to prevention programs conducted via pharmacies was a dominant option providing both cost savings and QALY gains. The highest savings can be potentially reached by targeting recruitment at men at elevated risk of T2D. Supplementary Information The online version contains supplementary material available at 10.1186/s12913-021-06948-6.
Collapse
Affiliation(s)
- Kari Jalkanen
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland.
| | - Emma Aarnio
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
| | - Piia Lavikainen
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
| | - Jaana Lindström
- Department of Public Health Solutions, Finnish Institute for Health and Welfare, P.O. Box 30, 00271, Helsinki, Finland
| | - Markku Peltonen
- Department of Public Health Solutions, Finnish Institute for Health and Welfare, P.O. Box 30, 00271, Helsinki, Finland
| | - Tiina Laatikainen
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Faculty of Medicine, P.O. Box 1627, 70211, Kuopio, Finland.,Chronic Disease Epidemiology and Prevention Unit, Finnish Institute for Health and Welfare, Helsinki, Finland.,Joint Municipal Authority for North Karelia Health and Social Services (Siun Sote), Joensuu, Finland
| | - Janne Martikainen
- Faculty of Health Sciences, School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
| |
Collapse
|
8
|
Lewicki J, Religioni U, Merks P. Evaluation of the Community Pharmacy Comorbidities Screening Service on Patients with Chronic Diseases. Patient Prefer Adherence 2021; 15:1611-1619. [PMID: 34305397 PMCID: PMC8294810 DOI: 10.2147/ppa.s312341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Accepted: 06/24/2021] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVE Evaluation of the implementation of pharmaceutical services to detect comorbidities in at-risk patients. METHODS This study was carried out in community pharmacies across Poland in 2019 inside the specially designed service "Refer the Patient". The project was intended for patients with selected chronic diseases. The patients were identified on the basis of their medications (active substances). At-risk patients were referred for prophylactic examinations to detect comorbidities. RESULTS A total of 78 pharmacies took part in this study and 209 at-risk patients were identified. Out of the patients referred for examinations, 30% had deviant results, and 0.95% were diagnosed with new diseases. CONCLUSION Pharmaceutical services supporting screening tests among at-risk patients are highly recommended. Pharmacist intervention allows for early detection of comorbidities and prompt treatment. The pharmaceutical service "Refer the Patient" makes it possible to detect a disease at an early stage. Rapid implementation of treatment can prevent serious health consequences, maintains patient quality of life, and reduce treatment costs.
Collapse
Affiliation(s)
- Jędrzej Lewicki
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland
| | - Urszula Religioni
- Collegium of Business Administration, Warsaw School of Economics, Warsaw, Poland
| | - Piotr Merks
- Faculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszyński University, Warsaw, Poland
- Correspondence: Piotr MerksFaculty of Medicine, Collegium Medicum, Cardinal Stefan Wyszynski University in Warsaw, Wóycickiego 1, Warsaw, 01-938, Poland Email
| |
Collapse
|
9
|
Miller P, Newby D, Walkom E, Schneider J, Li SC. Depression screening in adults by pharmacists in the community: a systematic review. INTERNATIONAL JOURNAL OF PHARMACY PRACTICE 2020; 28:428-440. [PMID: 32776433 DOI: 10.1111/ijpp.12661] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Revised: 06/01/2020] [Accepted: 07/06/2020] [Indexed: 11/08/2023]
Abstract
BACKGROUND Improving the identification of depression in adults in primary care can produce clinical and economic benefits. Community Pharmacists may play a role in screening for depression. OBJECTIVE To systematically review and evaluate the evidence for the feasibility, impact and cost-effectiveness of community pharmacists screening adults for depression. METHODS An electronic literature search using the databases EMBASE, PubMed and CINAHL Complete from January 2000 to September 2019 was undertaken to identify studies involving community pharmacists screening for depression. Data relating to sample size, population demographics and medical conditions of adults screened were extracted. Details around the screening model, process-related outcomes, clinical outcomes and economic outcomes were also extracted. RESULTS Ten studies using eight unique depression screening tools were identified. Ease of administration was the most common selection criterion (n = 4) while no reason was given in four studies. Seven studies reported that through screening, pharmacists could identify adults with undiagnosed depression. Pharmacists referred adults screening positive for assessment in seven studies and followed up participants in two studies. No study assessed the impact of screening on depressive symptoms or the cost-effectiveness of pharmacists screening for depression. CONCLUSION Community pharmacists are able to use depression screening tools to identify undiagnosed adults having symptoms of depression. However, there is little evidence around the impact of this screening on clinical and economic outcomes. Larger, well-designed studies that use a highly accurate, easily administered screening tool and include patient referral and follow-up and pharmacist training are warranted to provide evidence on the impact of community pharmacists screening adults for depression.
Collapse
Affiliation(s)
- Peter Miller
- School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Calvary Mater Newcastle Hospital, Waratah, NSW, Australia
| | - David Newby
- Pharmacy and Experimental Pharmacology, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia
| | - Emily Walkom
- School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Calvary Mater Newcastle Hospital, Waratah, NSW, Australia
| | - Jennifer Schneider
- School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, New Lambton Heights, NSW, Australia
| | - Shu Chuen Li
- Pharmacy and Experimental Pharmacology, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia
| |
Collapse
|